# Sniper

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/sniper

- Industry: Medical Devices & Equipment
- Headquarters: Suzhou, China
- Website: www.sniper-tech.com
- Total disclosed funding: $49M
- Latest round: Series B (Oct 31, 2024)
- Investors on record: 8

## About

Based in Suzhou, China and founded in 2018, Sniper is a developer of analytical medical instrument. At present, the company has completed the construction of instrument R & D laboratory, equipment manufacturing workshop and reagent production GMP workshop. In October 2024, Sniper closed a series B+ funding led by returning investor HM Capital, with participation from other returning investor Co-Win Ventures and new investor Leading Capital.

The company's product, DQ24 PCR System, is an all-in-one equipment – Press the start button and no more operations are needed. The full duration of the experiments is less than 2 hr. It has 6 fluorescence channels for users to choose from and optical design eliminates crosstalk of signals and ensures results.

The company generates revenue by selling analytical medical instruments.

The company will use the funds for marketing, related reagent product line development and large-scale expansion of overseas markets.

## Funding rounds

- Series B, Oct 31, 2024, $18M — Leading Capital, Co-Win Ventures, HM Capital
- Series B, Sep 27, 2021, $31M — Lotus Lake Capital, Alwin Capital, Apricot Capital, HM Capital, Huangpu Pharmaceutical Fund
- Series A, Apr 8, 2019 — Lotus Lake Capital, Alwin Capital, Zhongguancun Qihang Fund
- Angel, Aug 6, 2018 — Co-Win Ventures

## Investors

- Co-Win Ventures (https://capitalatlas.ai/funds/co-win-ventures) — Angel, Series B
- Lotus Lake Capital (https://capitalatlas.ai/funds/lotus-lake-capital) — Series A, Series B
- Alwin Capital — Series A, Series B
- Zhongguancun Qihang Fund — Series A
- Apricot Capital (https://capitalatlas.ai/funds/apricot-capital) — Series B
- HM Capital (https://capitalatlas.ai/funds/hm-capital) — Series B
- Huangpu Pharmaceutical Fund — Series B
- Leading Capital — Series B